



SCIENTIFIC PUBLICATION LIST

April 2016



www.resonancehealth.com

info@resonancehealth.com

FERRISCAN SCIENTIFIC PUBLICATION LIST

KEY PAPERS

St. Pierre TG et al. Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance. *Blood* 2005; 105 (2):855-861. [[Link to abstract](#)]

Pavitt H et al. The effect of reducing repetition time TR on the measurement of liver R2 for the purpose of measuring liver iron concentration. *Mag Reson Med*. 2011; 65(5):1346-51. [[Link to abstract](#)]

Brown GC et al. Spin-density-projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia. *Int Med J*. 2012; 30 May. DOI:10.1111/j.1445-5994.2012.02845.x. [[Link to abstract](#)]

Taher AT et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1 year results from a prospective, randomized, double-blind, placebo-controlled study. *American Society of Haematology*. 2012; 120:970-77. [[Link to abstract](#)]

St Pierre TG et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. *Magn Reson Med*. (2013), doi: 10.1002/mrm.24 [[Link to paper](#)]

Taher, AT et al. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. *American Journal of Hematology*, 2013. 88(6): p. 503-506. doi:10.1002/ajh.23445. [[Link to abstract](#)]

GUIDELINES

Tubman, VN, et al. Guidelines for the Standard Monitoring of Patients With Thalassemia: Report of the Thalassemia Longitudinal Cohort. *Journal of pediatric hematology/oncology*, 2015. 37(3): p. e162-e169. [[Link to guideline](#)]

Thalassaemia International Federation. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT) 3rd Edition 2014. Porter, J et al. in *Iron Overload and Chelation*. [[Link to guideline](#)]

Royal College of Obstetricians and Gynaecologists (UK). Management of Beta Thalassaemia in Pregnancy Green-Top Guideline no. 66. 2014. [[Link to guideline](#)]

ASH Education Program Book, 2013. Consequences and management of iron overload in sickle cell disease. Porter, J and M Garbowski. 2013(1): p. 447-456. [[Link to guideline](#)]

The Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance -Long-term follow-up after hematopoietic stem cell transplant general guidelines for referring physicians (April 2013) [[Link to guideline](#)]

University Health Network - Toronto General Hospital. Guidelines for the care of patients in UHN Red Blood Cell Disorders Program. 2012. [[Link to guideline](#)]

Northern California Comprehensive Thalassemia Network and Children's Hospital, Oakland. 2012 Thalassemia Standards of Care Guidelines. [[Link to guideline](#)]

Centres for Disease Control (CDC) - Diamond Blackfan Anemia Chelation Therapy Fact Sheet. [[Link to factsheet](#)]

Ho PJ et al. Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias. *Internal Medicine Journal*. 2011; 41(7): 516-24. [[Link to abstract](#)]

Santini V et al. Clinical Management of myelodysplastic syndromes: updated of SIE, SIES, GITMO practice guidelines. *Leukemia Research*. 2010; 34:1576-88. [[Link to abstract](#)]

Cooley's Anemia Foundation. 2010 Position Statement on MRI-Based Hepatic Iron Assessment Methods. [[Link to guideline](#)]

Angelucci E et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassaemia major and related disorders. *Haematologica* 2008;93(5):741-752. [[Link to full article](#)]

Wells D et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. *Leukemia Research*. 2008; 32(9):1338-53. [[Link to abstract](#)]

Thalassemia International Federation. Guidelines for the clinical management of Thalassaemia (2nd revised edition). 2008. [[Link to guideline](#)]

UK Thalassaemia Society. Standards for the clinical care of children and adults with Thalassaemia in the UK (2nd edition). 2008. [[Link to guideline](#)]

UK Sickle Cell Society. Standards for the clinical care of adults with sickle cell disease in the UK (1st edition). 2008. [[Link to guideline](#)]

International Association of Sickle Cell Nurses and Physician Assistants. Nursing Practice Guideline: Care of the patients with sickle cell disease and iron overload. 2008. http://www.iascnapa.org/guidelines/Guidelines_IronOverload.pdf

FERRISCAN SCIENTIFIC PUBLICATION LIST

ORIGINAL ARTICLES

- Taher, AT, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. *Blood Cells, Molecules, and Diseases*, 2016. 57: p. 23-29. doi: 10.1016/j.bcmd.2015.11.002 [[Link to full article](#)]
- Fasano, RM, et al. Effectiveness of red blood cell exchange, partial manual exchange, and simple transfusion concurrently with iron chelation therapy in reducing iron overload in chronically transfused sickle cell anemia patients. *Transfusion*, 2016: p. n/a-n/a. doi: 10.1111/trf.13558 [[Link to abstract](#)]
- Tsitsikas, DA, et al. Safety, tolerability, and outcomes of regular automated red cell exchange transfusion in the management of sickle cell disease. *Journal of Clinical Apheresis*, 2016. doi: 10.1002/jca.21447 [[Link to abstract](#)]
- Holman, R, et al. Characterisation of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. *Nephrology*, 2016. doi: 10.1111/nep.12735 [[Link to abstract](#)]
- Schempp, A, et al. Iron Overload in Survivors of Childhood Cancer. *Journal of Pediatric Hematology/Oncology*, 2016. 38(1): p. 27-31. [[Link to abstract](#)]
- Vitrano, A, et al. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET. *European Journal of Haematology*, 2016. doi: 10.1111/ejh.12740 [[Link to abstract](#)]
- Calvaruso, G, et al. Exon 12 Ceruloplasmin Gene New Nonsense Mutation Causing Aceruloplasminemia in an Italian Patient. *Open Journal of Internal Medicine*, 2016. 6(01): p. 20. doi: [10.4236/ojim.2016.61005](#) [[Link to full article](#)]
- Taher, AT, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. *British Journal of Haematology*, 2015. 168(2): p. 284-290. doi:10.1111/bjh.13119 [[Link to abstract](#)]
- Jones, E, et al. Hcpidin is suppressed by erythropoiesis in hemoglobin E β -thalassaemia and β -thalassaemia trait. *Blood*, 2015. 125(5): p. 873-880. [[Link to full article](#)]
- Chowdhury, P, et al. Correlation of Serum Ferritin with Hepatic Iron Overload among Nontransfusion Dependent Beta Thalassaemia with Haemoglobin E Disease Patients from Eastern India. *Journal of Molecular Biomarkers & Diagnosis*, 2015. 6(3): p. 1. doi:10.4172/2155-9929.1000231 [[Link to full article](#)]
- Adams, LA, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. *Hepatology*, 2015. 61(5): p. 1555-1564. doi: 10.1002/hep.27662 [[Link to abstract](#)]
- Kohgo, Y, et al. Deferasirox decreases liver iron concentration in iron-overloaded patients with myelodysplastic syndromes, aplastic anemia and other rare anemias. *Acta Haematologica*, 2015. 134(4): p. 233-242. doi: 10.1159/000381893 [[Link to full article](#)]
- Luo, XF, et al. Dual-Energy CT for Patients Suspected of Having Liver Iron Overload: Can Virtual Iron Content Imaging Accurately Quantify Liver Iron Content? *Radiology*, 2015. 277(1): p. 95-103. doi: [10.1148/radiol.2015141856](#) [[Link to abstract](#)]
- Sharma, SD, et al. Quantitative susceptibility mapping in the abdomen as an imaging biomarker of hepatic iron overload. *Magnetic Resonance in Medicine*, 2015. 74(3): p. 673-683. doi: 10.1002/mrm.25448 [[Link to abstract](#)]
- Wood, JC, et al. Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results. *Magnetic Resonance Imaging*, 2015. 33(6): p. 761-767. doi: 10.1016/j.mri.2015.02.016 [[Link to abstract](#)]
- Tsouana, E, et al. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical haemoglobinopathy network. *European Journal of Haematology*, 2015. 94(4): p. 336-342. Doi: 10.1111/ejh.12435 [[Link to abstract](#)]
- Gutiérrez, L, et al. Tissue Iron Distribution Assessed by MRI in Patients with Iron Loading Anemias. *PLoS ONE*, 2015. 10(9): p. e0139220. doi: 10.1371/journal.pone.0139220 [[Link to full article](#)]
- Serai, SD, et al. Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents. *Pediatric Radiology*, 2015. 45(11): p. 1629-1634. doi: 10.1007/s00247-015-3378-9 [[Link to abstract](#)]
- Taher, AT, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. *European Journal of Haematology*, 2014. 92(6): p. 521-526. doi: 10.1111/ejh.12270 [[Link to abstract](#)]
- Ang, AL, et al. History of myocardial iron loading is a strong risk factor for diabetes mellitus and hypogonadism in adults with β thalassaemia major. *European Journal of Haematology*, 2014. 92(3): p. 229-236. doi:10.1111/ejh.12224 [[Link to abstract](#)]
- Tsitsikas, DA, et al. Comparison of serial serum ferritin measurements and liver iron concentration assessed by MRI in adult transfused patients with sickle cell disease. *European Journal of Haematology*, 2014. 92(2): p. 164-167. doi: 10.1111/ejh.12230 [[Link to abstract](#)]
- Tzoulis, P, et al. Joint diabetes thalassaemia clinic: An effective new model of care. *Hemoglobin*, 2014. 38(2): p. 104-110. doi: 10.3109/03630269.2013.862541 [[Link to abstract](#)]
- El Beshlawy, A, et al. Low prevalence of cardiac siderosis in heavily iron loaded Egyptian thalassaemia major patients. *Annals of Hematology*, 2014. 93(3): p. 375-379. doi: 10.1007/s00277-013-1876-0 [[Link to abstract](#)]
- Wood, JC, et al. R2 and R2* are equally effective in evaluating chronic response to iron chelation. *American Journal of Hematology*, 2014. 89(5): p. 505-508. doi: 10.1002/ajh.23673 [[Link to abstract](#)]
- Cheong, J-W, et al. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. *Transfusion*, 2014. 54(6): p. 1542-1551. doi: 10.1111/trf.12507 [[Link to abstract](#)]
- Garbowski, MW, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. *Journal of Cardiovascular Magnetic Resonance*, 2014. 16: p. 11. doi: 10.1186/1532-429x-16-40 [[Link to full article](#)]

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Chan, WC, et al. R2* as a surrogate measure of ferriscan iron quantification in thalassemia. *Journal of Magnetic Resonance Imaging*, 2014. 39(4): p. 1007-1011. doi: 10.1002/jmri.24216 [\[Link to abstract\]](#)
- Nichols-Vinueza, DX, et al. MRI guided iron assessment and oral chelator use improve iron status in thalassemia major patients. *American Journal of Hematology*, 2014. 89(7): p. 684-688. doi: 10.1002/ajh.23715 [\[Link to abstract\]](#)
- Viprakasit, V, et al. Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. *Blood Transfusion*, 2013. 11(1): p. 108-122. [\[Link to full article\]](#)
- Hernando, D, et al. Magnetic susceptibility as a B0 field strength independent MRI biomarker of liver iron overload. *Magnetic Resonance in Medicine*, 2013. 70(3): p. 648-656. doi: 10.1002/mrm.24848 [\[Link to abstract\]](#)
- Trottier, BJ, et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. *Blood*, 2013. 122(9): p. 1678-1684. [\[Link to full article\]](#)
- Porter JB et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging sub study. *Ann Hematol*.2013 Jan;92(2):211-9 [\[Link to abstract\]](#)
- Nolte F et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. *Ann Hematol*. 2013 Jan;92(2):191-8 [\[Link to abstract\]](#)
- Wermke M et al. MRI-based liver iron content predicts for non-relapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. *Clinical Cancer Research*. 2012; Sept 18. DOI:10.1158/1078-0432.CCR-12-1683 [Epub ahead of print]. [\[Link to abstract\]](#)
- Kwiatkowski J et al. Chelation use and iron burden in North America and British Thalassemia patients: a report from the Thalassemia Longitudinal Cohort. *Blood*. 2012; 119:2746-2753. [\[Link to abstract\]](#)
- St Pierre TG et al. Spin-density-projection-assisted R2 magnetic resonance imaging of the liver in the management of body iron stores in patients receiving multiple red blood cell transfusions: an audit and retrospective study in South Australia. *Internal Medicine Journal*. 2012; 42(9):990-6. doi: 10.1111/j.1445-5994.2012.02845.x [\[Link to abstract\]](#)
- Neufeld EJ et al. A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. *Blood*. 2012; 119:3263-8. [\[Link to abstract\]](#)
- Cheng H-L et al. Liver iron overload assessment by T2* magnetic imaging in pediatric patients: An accuracy and reproducibility study. *Am J Hematol*. 2012; Jan 28. DOI: 10.1002/ajh.23114 [\[Link to abstract\]](#)
- Vasavda A et al. Renal iron load in sickle cell disease is influenced by severity of hemolysis. *Brit J Haematol*. 2012; 157(5):599-605. Doi: 10.1111/j.1365-2141.2012.09093.x [\[Link to abstract\]](#)
- Drasar E et al. Serum ferritin and total units transfused for assessing iron overload in adults with sickle cell disease. *Brit J Haematol*. 2012; 157:637-50. [\[Link to full article\]](#)
- Taher A et al. Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β -thalassaemia. *Eur J Haem*. 2011; 87:355-65. [\[Link to abstract\]](#)
- Pavitt H et al. The effect of reducing repetition time TR on the measurement of liver R2 for the purpose of measuring liver iron concentration. *Mag Reson Med*. 2011; 65(5):1346-51. [\[Link to abstract\]](#)
- Pennell DJ et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. *Haematologica*. 2011; 96(1):48-54. [\[Link to abstract\]](#)
- Ferrari P et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. *Clin J Am Soc Nephrol*. 2011; 6(1):77-83. [\[Link to abstract\]](#)
- Musallam KM et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta-thalassaemia intermedia. *Haematologica*. 2011. 96(11):1605-12. [\[Link to abstract\]](#)
- Inati A et al. Non-transferrin bound iron in transfused patients with sickle cell disease. *Int J Lab Hematol*. 2011; 33(2):133-7. [\[Link to abstract\]](#)
- Taher A et al. Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β -thalassaemia: results from the ESCALATOR study. *European J Haematol*. 2011; 87(4):349-54. [\[Link to abstract\]](#)
- House M et al. Relationship between brain R(2) and liver and serum iron concentrations in elderly men. *Mag Reson Med*. 2010; 63:275-81. [\[Link to abstract\]](#)
- Patton N et al. Observational study of iron overload as assessed by magnetic resonance imaging (MRI) in an adult population of transfusion dependent patients with beta thalassaemia: Significant association between low cardiac T2* < 10 ms and the occurrence of cardiac events. *Intern Med J* 2010; 40: 419-26. [\[Link to abstract\]](#)
- Greenberg P et al. Prospective assessment of effects of iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. *Leuk Res*. 2010; 34(12):1560-5. [\[Link to abstract\]](#)
- Majhail NS et al. A prospective study of iron-overload management in allogeneic hematopoietic-cell transplant survivors. *Biol Blood Marrow Transplant*. 2010; 16(5):832-7. [\[Link to abstract\]](#)
- Pathare A et al. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. *Ann Hematol* 2010; 89(4):405-9. [\[Link to abstract\]](#)
- Pennell DJ et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β -thalassaemia. *Blood* 2010; 115(12):2364-71. [\[Link to abstract\]](#)
- Taher A et al. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. *Am J Hematol*. 2010; 85(4): 288-90. [\[Link to abstract\]](#)
- Taher A et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. *Br J Haematol* 2009;146(5):569-572. [\[Link to abstract\]](#)
- Inati A et al. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. *Eur J Haematol* 2009; 83(6):565-71. [\[Link to abstract\]](#)

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Majhail NS et al. Iron-overload after autologous hematopoietic cell transplantation. *Leuk Res* 2009;33(4):578-579. [[Link to abstract](#)]
- Olynyk J et al. Predicting iron overload in hyperferritinemia. *Clinical Gastroenterology and Hepatology*. 2009;7(3):359-362. [[Link to abstract](#)]
- Angulo IL et al. Determination of iron-overload in thalassemia by hepatic MRI and ferritin. *Revista Brasileira De Hematologia E Hemoterapia* 2008;30(6):449-452. [[Link to full text](#)]
- Isma'eel H et al. Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia. *Am J Cardiol* 2008;102(3):363-367. [[Link to abstract](#)]
- Majhail NS et al. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. *Biol Blood Marrow Transplant* 2008;14(7):790-794. [[Link to abstract](#)]
- Melis MA et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. *Haematologica* 2008;93(10):1473-1479. [[Link to abstract](#)]
- Origa R et al. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. *Haematologica* 2008;93(7):1095-1096. [[Link to full article](#)]
- Taher A et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. *Haematologica* 2008;93(10):1584-1586. [[Link to full text article](#)]
- Carneiro AA et al. Liver iron concentration evaluated by two magnetic methods: magnetic resonance imaging and magnetic susceptometry. *Magn Reson Med* 2005;54(1):122-128. [[Link to abstract](#)]
- Olynyk JK et al. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. *Am J Gastroenterol* 2005;100(4):837-841. [[Link to abstract](#)]
- St Pierre TG et al. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. *Ann N Y Acad Sci*. 2005;1054:379-85. [[Link to abstract](#)]
- St Pierre TG et al. Single spin-echo proton transverse relaxometry of iron-loaded liver. *NMR Biomed* 2004;17(7):446-458. [[Link to abstract](#)]
- Clark PR et al. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. *Magn Reson Imaging* 2003;21(5):519-530. [[Link to abstract](#)]
- Clark PR et al. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI. *Magn Reson Med*. 2003 Mar;49(3):572-5. [[Link to abstract](#)]

EDITORIALS

Angelucci, E. Another Step Forward in Iron Chelation Therapy. *Acta Haematologica*, 2015. 134(4): p. 231-232. doi: 10.1159/000431215 [[Link to abstract](#)]

Savani, BN. Ferritin and FerriScan in HCT recipients. *Blood*, 2013. 122(9): p. 1539-1541. doi: 10.1182/blood-2013-07-511014 [[Link to full article](#)]

REVIEW ARTICLES

Murray, C, et al. Management of iron overload in the Canadian hematology/oncology population: Implications for nursing practice. *Canadian Oncology Nursing Journal/Revue canadienne de soins infirmiers en oncologie*, 2016. 26(1): p. 19-28. [[Link to full article](#)]

Sarigianni, M, et al. Accuracy of Magnetic Resonance Imaging in Diagnosis of Liver Iron Overload: A Systematic Review and Meta-analysis. *Clinical Gastroenterology and Hepatology*, 2015. 13(1): p. 55-63.e5. doi: 10.1016/j.cgh.2014.05.027 [[Link to abstract](#)]

Quinn, CT and TG St Pierre. MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls. *Pediatric Blood & Cancer*, 2015. doi: 10.1002/pbc.25882 [[Link to abstract](#)]

Wood, JC. Estimating tissue iron burden: current status and future prospects. *British Journal of Haematology*, 2015 doi: 10.1111/bjh.13374 [[Link to abstract](#)]

Hansen, L and SS Slater. Long-Term Follow-Up and Survivorship, in *Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care*, TR Maziarz and SS Slater, Editors. 2015, Springer International Publishing: Cham. p. 407-426. doi: 10.1007/978-3-319-13832-9_34 [[Link to abstract](#)]

Hernando, D, et al. Quantification of liver iron with MRI: State of the art and remaining challenges. *Journal of Magnetic Resonance Imaging*, 2014 doi: 10.1002/jmri.24584 [[Link to abstract](#)]

Sheth, S. Iron chelation: an update. *Current Opinion in Hematology*, 2014. 21(3): p. 179-185. [[Link to abstract](#)]

Wood, JC. Use of Magnetic Resonance Imaging to Monitor Iron Overload. *Hematology-Oncology Clinics of North America*, 2014. 28(4): p. 747. [[Link to first page preview](#)]

Hope, TA, et al. MR imaging of diffuse liver disease: from technique to diagnosis. *Radiologic Clinics of North America*, 2014. 52(4): p. 709-724. [[Link to first page preview](#)]

Alexiou, E. Methodologies and tools used today for measuring iron load. *Thalassemia Reports*, 2014. 4(3). [[Link to full article](#)]

Holman, R. Clinical edge: Diagnosing haemochromatosis. *Medicus*, 2013. 53(6): p. 46.

Olivieri, NF and GM Brittenham. Management of the Thalassemias. *Cold Spring Harbor Perspectives in Medicine*, 2013. 3(6). [[Link to full article](#)]

Castiella, A, et al. Is MRI becoming the new gold standard for diagnosing iron overload in hemochromatosis and other liver iron disorders? *Imaging in Medicine*, 2013. 5(6): p. 515-524.

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Towbin, AJ, et al. Magnetic Resonance Imaging of the Pediatric Liver: Imaging of Steatosis, Iron Deposition, and Fibrosis. *Magnetic Resonance Imaging Clinics of North America*, 2013. 21(4): p. 669-680. [[Link to first page preview](#)]
- Shibata, M and S Taniguchi. Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis. *Cardiovascular & Haematological Disorders - Drug Targets (Formerly Current Drug Targets - Cardiovascular & Haematological Disorders)*, 2013. 13(3): p. 237-242. [[Link to abstract](#)]
- Ware HM, Kwiatkowski JL: Optimal use of iron chelators in pediatric patients. *Clinical Advances in Hematology & Oncology* 2013, 11:433-441. [[Link to full article](#)]
- Juchems MS et al. Liver iron content determined by MRI: Spin-Echo vs Gradient-Echo. *Rofo*. 2012; 184: 427-431. [[Link to abstract](#)]
- Kruger PC et al. Assessing iron overload: Are we there yet? *Clin Cancer Res*. 2012. Nov 19. Epub ahead of print. [[Link to abstract](#)]
- Fleming RE and Ponka P. Iron overload in human disease. *N Engl J Med*. 2012; 366:348-59 [[Link to abstract](#)]
- Alustiza Echeverria JM et al. Quantification of iron concentration in the liver by MRI. *Insights Imaging*. 2012; 3:173-80. [[Link to abstract](#)]
- Bird RJ et al. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? *Internal Medicine Journal*. 2012; 42:450-5. [[Link to abstract](#)]
- Muñoz M. et al. Disorders of iron metabolism. Part II: iron deficiency and iron overload. *J Clin Pathol*. 2011;64:287-296 [[Link to paper](#)]
- Kwiatkowski J. Management of transfusional iron overload - differential properties and efficacy of iron chelating agents. *J Blood Med*. 2011; 2(135-149). [[Link to abstract](#)]
- Taher AT et al. Optimal management of β -thalassaemia intermedia. *British Journal of Haematology*. 2011; 152: 512-23. [[Link to abstract](#)]
- Cao A et al. Recent advances in β -thalassemias. *Pediatric Reports*. 2011; 3:e17. [[Link to abstract](#)]
- Tziomalos K and Perifanis V. Liver iron content determination by magnetic resonance imaging. *World J Gastro*. 2010. 16(13): 1587-97. [[Link to abstract](#)]
- Araujo A et al. Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations. *Hematology* 2009;14(1):22-32. [[Link to abstract](#)]
- Cappellini M et al. Insight onto the pathophysiology and clinical complications of thalassaemia intermedia. *Hemoglobin* 2009; 33(S1): S145-S159. doi: 10.3109/03630260903351528 [[Link to abstract](#)]
- El Rassi F et al. Beta-thalassaemia intermedia: an overview. *Pediatr Ann* 2008;37(5):322-328. [[Link to PubMed listing](#)]
- Majhail NS et al. Iron overload in hematopoietic cell transplantation. *Bone Marrow Transplant* 2008;41(12):997-1003. [[Link to abstract](#)]
- Wood J et al. Magnetic Resonance Imaging assessment of excess iron in thalassaemia, sickle cell disease and other iron overload diseases. *Hemoglobin* 2008;32(1-2):85-96. [[Link to full article](#)]
- Alustiza JM et al. Iron overload in the liver diagnostic and quantification. *Eur J Radiol* 2007;61(3):499-506. [[Link to abstract](#)]
- Pavenski K et al. The real cost of iron chelation therapy. *Transfusion* 2007;47(10):1751-1752. [[Link to Pubmed listing](#)]
- Wood J et al. Magnetic resonance imaging measurement of iron overload. *Curr Opin Hematology* 2007;14(3):183-190. [[Link to full article](#)]
- Neufeld E. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassaemia major; new data, new questions. *Blood*. 2006; 107:3436-3441. doi: 10.1182/blood-2006-02-002394 [[Link to full article](#)]
- Zoller H et al. Hemochromatosis: genetic testing and clinical practice. *Clin Gastroenterol Hepatol* 2005;3(10):945-958. [[Link to abstract](#)]
- Rossi E et al. Clinical Penetrance of C282Y Homozygous HFE Haemochromatosis. *Clin Biochem Rev* 2004;25(3):183-190. [[Link to abstract](#)]

CONFERENCE PROCEEDINGS

- Chowdhury, PK, et al. Profile of Iron Overload in Nontransfusion Dependent Hb E Beta Thalassaemia Patients- Is It Different? *Blood*, 2015. 126(23): p. 4557. [[Link to abstract](#)]
- Ware, RE, et al. TCD with Transfusions Changing to Hydroxyurea (TWITCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. *Blood*, 2015. 126(23): p. 3-3. [[Link to abstract](#)]
- Yassin, MA, et al. Increased Liver Iron Concentration (LIC) in Adults with Non-Transfusion Dependent Sickle Cell Disease (NTD-SCD): Correlation with Serum Ferritin Concentrations. *Blood*, 2015. 126(23): p. 4594. [[Link to abstract](#)]
- Vitrano, A, et al. Different Thresholds of Serum Ferritin Levels for Prediction of Liver Iron Concentration in Hemoglobinopathies. *Blood*, 2015. 126(23): p. 2146. [[Link to abstract](#)]
- Calvaruso, G, et al. Central Role of LIC-R2 (Ferriscan®) Determination in Patients with Hemoglobinopathies: LICNET Experience. *Blood*, 2014. 124(21): p. 4034. [[Link to abstract](#)]
- Brown, RC, et al. A Quick, Robust Protocol for Liver Iron Quantitation on 3.0 Tesla MRI Scanners. *Blood*, 2014. 124(21): p. 4069. [[Link to abstract](#)]
- Ezzat, H. Utility of Transient Elastography (Fibroscan) in Estimating Hepatic Iron Concentration in Comparison to MRI in Patients with Transfusion Dependent Hemoglobinopathies. *Blood*, 2014. 124(21): p. 4888. [[Link to abstract](#)]
- Wood, JC, et al. Liver Iron Concentration By MRI In Chronically Transfused Children With Sickle Cell Anemia In The Twitch Trial. *Blood*, 2013. 122(21): p. 780. [[Link to abstract](#)]
- Wood, JC, et al. R2 and R2* Are Equally Effective In Evaluating Chronic Response To Iron Chelation. *Blood*, 2013. 122(21): p. 3437. [[Link to abstract](#)]
- St Pierre, TG, et al. Assessment Of Non-Transfusional Iron Accumulation In Asian Patients With Hemoglobin E β Thalassaemia. *Blood*, 2013. 122(21): p. 2262. [[Link to abstract](#)]

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Nichols-Vinueza, DX, et al.** MRI-Guided Iron Assessment and Oral Chelator Use Improve Iron Status In Thalassemia Major Patients: a Six-Year Single Center Retrospective Cohort Study. *Blood*, 2013. 122(21): p. 563. [\[Link to abstract\]](#)
- Taher A et al.** Deferasirox significantly reduces liver iron concentration in non-transfusion-dependent Thalassemia patients with iron overload: results from the 1-year randomised, double-blind, placebo-controlled phase II THALASSA study. ASH Annual Meeting. 2011; Abstract 902.
- Neufeld E et al.** Safety, tolerability and dose response of FBS0701, a novel iron chelator for treatment of transfusional iron overload: results of a 24-week multi-centre, international Phase 2 study. ASH Annual Meeting. 2011; Abstract 690.
- Min Y-H et al.** Hematologic improvement with iron chelation using therapy Deferasirox in patients with aplastic anemia: A subgroup analysis of KAMS0112 prospective study. ASH Annual Meeting. 2011; Abstract 3424.
- Vasavda N et al.** Renal iron load in sickle cell disease correlates with hemolysis and transfusion history, but not with hepatic iron. ASH Annual Meeting. 2011; Abstract 2129.
- Inati A et al.** Relationship between total iron removed by phlebotomy and iron removed from the liver in pediatric thalassemia major patients following curative stem cell transplant. ASH Annual Meeting. 2011; Abstract 5300.
- Kogho Y et al.** Deferasirox decreases liver iron concentration (LIC) in transfusional iron overloaded patients with myelodysplastic syndromes (MDS), aplastic anemia (AA) and other rare anemias: Results from 1-year multi-centre, open-label phase II study. ASH Annual Meeting. 2011; Abstract 4838.
- Gatterman N et al.** Transfused myelodysplastic syndromes (MDS) patients have severe iron overload and relevant improvements in iron burden and liver function with deferasirox treatment: results from a pooled analysis. ASH Annual Meeting. 2011; Abstract 5019.
- Blair AB et al.** Transfusional iron overload in acute lymphoblastic leukemia. In: Arceci RJ, editor. American Society of Pediatric Hematology/ Oncology - 22nd Annual Meeting San Diego, California April 22-25, 2009. Volume 52: *Pediatric Blood & Cancer*; 2009. p 707. Poster 124.
- Cheong J-W et al.** Efficacy of ICT with Deferasirox in transfusional iron overload patients with MDS or AA. ASH Annual Meeting Abstract. 2009; Abstract 3810. [\[Link to abstract\]](#)
- Pennell D et al.** Efficacy and safety of Deferasirox (Exjade®) in β -thalassemia patients with myocardial siderosis - 2 year results from the EPIC cardiac sub-study. ASH Annual Meeting Abstract. 2009; Abstract 4062. [\[Link to abstract\]](#)
- Taher A et al.** Deferasirox (Exjade®) \geq 30 mg/kg/day is effective in reducing iron burden in thalassemia major patients previously chelated with monotherapy or combination therapy. ASH Annual Meeting Abstract. 2009; Abstract 4058. [\[Link to abstract\]](#)
- Min Y et al.** A multi-centre, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R₂ MRI. *Leukaemia Research* 33: Supplement 1. 2009:S119-S120.
- Capellini M et al.** Efficacy and safety of once-daily iron chelator Deferasirox (Exjade®) in a large group of regularly transfused patients with β -thalassemia major. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3878. [\[Link to abstract\]](#)
- Capellini M et al.** Efficacy and safety of Deferasirox (Exjade®) in patients with transfusion-dependent anemias: 1 year results from the large, prospective, multi-centre, EPIC study. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3875. [\[Link to abstract\]](#)
- Porter J et al.** Efficacy and safety of 1 year's treatment with Deferasirox (Exjade®): Assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC study. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1046. [\[Link to abstract\]](#)
- Taher A et al.** Deferasirox (Exjade®) treatment in pediatric β -thalassemia patients with high iron burden: 2.8 years results from ESCALATOR trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3879. [\[Link to abstract\]](#)
- Taher A et al.** Efficacy and safety of once-daily oral deferasirox (Exjade®) during a median of 2.7 years of treatment in heavily iron-overloaded patients with β -thalassemia. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 5409. [\[Link to abstract\]](#)
- Porter J et al.** Deferasirox efficacy and safety for the treatment of transfusion-dependent iron overload in patients with a range of rare anemias. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1419. [\[Link to abstract\]](#)
- Porter J et al.** Effect of Deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective, 1-year EPIC trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3881. [\[Link to abstract\]](#)
- Pennell D et al.** Efficacy and safety of Deferasirox (Exjade®) in reducing cardiac iron in patients with β -thalassemia major: Results from the cardiac substudy of the EPIC trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3873. [\[Link to abstract\]](#)
- Pennell D et al.** Efficacy and safety of Deferasirox (Exjade®) in preventing cardiac iron in patients with normal baseline cardiac iron: Results from the cardiac substudy of the EPIC trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3874. [\[Link to abstract\]](#)
- Gatterman N et al.** Efficacy and safety of Deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: Results from EPIC trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 633. [\[Link to abstract\]](#)
- Porter J et al.** Efficacy and safety of 1 year's treatment with Deferasirox (Exjade®): Assessment of regularly transfused patients with Diamond-Blackfan anemia enrolled in the EPIC study. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 1048. [\[Link to abstract\]](#)
- Min Y-H et al.** A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R₂ MRI. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3649. [\[Link to abstract\]](#)

FERRISCAN SCIENTIFIC PUBLICATION LIST

- Lee J et al.** Iron chelation in regularly transfused patients with aplastic anemia: Efficacy and safety results from the large Deferasirox EPIC trial. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3649. [\[Link to abstract\]](#)
- Greenberg P et al.** Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of Deferasirox (DFX/Exjade®) therapy in a cohort of myelodysplastic patients. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 5083. [\[Link to abstract\]](#)
- Piga A et al.** Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with beta-thalassemia, treated with Deferasirox (ExJade(R), ICL670). *Blood* (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2689. [\[Link to abstract\]](#)
- St Pierre T et al.** A new model for predicting venesection therapy requirements in hereditary hemochromatosis using non-invasive liver iron concentration measurement. *Blood* (ASH Annual Meeting Abstracts) 2005; 1106: Abstract 3596.